MedTrace Logo

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

NCT04175431 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-18

No results posted yet for this study

Summary

This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.

Conditions

  • Prostate Adenocarcinoma

Interventions

PROCEDURE

Positron Emission Tomography

Undergo fluciclovine PET/CT

PROCEDURE

Lymphadenectomy

Undergo lymphadenectomy

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Abiraterone Acetate

Given PO

DRUG

Prednisone

Given PO

PROCEDURE

Computed Tomography

Undergo fluciclovine PET/CT

DRUG

Abiraterone

Given PO

PROCEDURE

PSMA PET Scan

Undergo PSMA PET scan

Sponsors & Collaborators

Principal Investigators

  • Evan Yu · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2028-07-01
Completion
2033-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175431 on ClinicalTrials.gov